• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

by Fred Pennic 05/20/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
White House, IBM Partner to Fight COVID-19 Using Supercomputers

What You Should Know: 

– The U.S. Department of Health and Human Services (HHS) announced it is taking immediate action to implement President Donald J. Trump’s Executive Order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” 

– Under the leadership of President Trump, HHS Secretary Robert F. Kennedy Jr., and Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz, the Department has outlined specific targets for pharmaceutical manufacturers. 

– The administration anticipates highlighting these commitments in the coming weeks, with the goal of ensuring Americans no longer face higher medication costs than patients in economically comparable nations.

The Most-Favored-Nation Pricing Mandate

HHS expects pharmaceutical manufacturers to commit to aligning U.S. prices for all brand-name products that do not currently face generic or biosimilar competition with the lowest price found among a set of peer countries. The Most-Favored-Nation (MFN) target price is defined as the lowest price in an Organisation for Economic Co-operation and Development (OECD) country that has a GDP per capita of at least 60 percent of the U.S. GDP per capita.

Expected Impact: Lower Costs While Aiming to Preserve Innovation

Officials state that these targets are designed to drastically reduce U.S. drug prices, which are often reported to be three to five times higher than those abroad. The administration asserts that this policy will relieve an unfair financial burden on Americans while preserving innovation, by ensuring U.S. patients do not bear a greater cost for the same drugs than patients in other developed nations. 

The administration frames the move as a necessary step to correct an unfair burden on U.S. consumers. “For too long, Americans have been forced to pay exorbitant prices for the same drugs that are sold overseas for far less,” said Secretary Kennedy. “That ends today. We expect pharmaceutical manufacturers to fulfill their commitment to lower prices for American patients, or we will take action to ensure they do.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Aidoc Secures $150M to Accelerate Enterprise-Scale Clinical AI Across 2,000 Hospitals

OpenAI Launches ChatGPT for Clinicians: Free AI Documentation and Research Tool for Verified Physicians

OpenAI Launches ChatGPT for Clinicians: Free AI Documentation and Research Tool for Verified Physicians

IKS Health Acquires TruBridge for Rural EHR and RCM Solutions Expansion

IKS Health Acquires TruBridge for Rural EHR and RCM Solutions Expansion

UT Austin is Building the Nation's First 'AI-Native' Hospital, Backed by $750M

Why UT Austin is Building an ‘AI-Native’ Hospital from Scratch

The Medtech Pitch Deck Casino: Why Hype Still Wins, and How Scrutiny Could Improve Everyone’s Odds

The Casino Model: Why Medtech VCs Are Betting Billions on Unproven AI

Oracle Lays Off 539 Kansas City Employees as Focus Shifts to AI Data Centers

Oracle Lays Off 539 Kansas City Employees as Focus Shifts to AI Data Centers

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

HHS Reverses 2024 Tech Reorganization: Why HHS Just Stripped AI and Cyber Operations Out of the ONC

How Small Medical Practices Can Build HIPAA-Aligned DevSecOps Without Enterprise Budgets

How Small Medical Practices Can Build HIPAA-Aligned DevSecOps Without Enterprise Budgets

Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration

Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration

Microsoft Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Microsoft Launches Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |